916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

R De Wit,G.S Kulkarni,E Uchio,J.L Boormans,M Roumiguié,L.E.M Krieger,E.A Singer,D.F Bajorin,A.M Kamat,P Grivas,H.K Seo,H Nishiyama,B.R Konety,T Saretsky,H Li,K Nam,E Sbar,A.V Balar

doi:10.1093/annonc/mdz249.015

916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

R De Wit, G.S Kulkarni + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz249.015

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 4	License type: publisher-specific-oa

Affiliation: Royal North Shore Hospital, The University of Texas MD Anderson Cancer Center

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

Full Text